专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007131042A2 CHROMOIONOPHORE AND METHOD OF DETERMINING POTASSIUM IONS 审中-公开
标题翻译：色谱法和测定钾离子的方法
公开(公告)号：WO2007131042A2
公开(公告)日：2007-11-15
申请号：PCT/US2007/068047
申请日：2007-05-02
申请人： OPTI MEDICAL SYSTEMS, INC , HE, Huarui , LIN, Chao , RAJE, Neeta , LIU, Chuseng
发明人： HE, Huarui , LIN, Chao , RAJE, Neeta , LIU, Chuseng
IPC分类号： G01N21/75
CPC分类号： G01N21/78 , G01N31/22
摘要： The invention relates to methods of determining potassium ions in a sample, wherein the ions are contacted with a compound having chromophoric moiety and an ionophoric moiety, where the ionophoric moiety interacts with the potassium ions present in the sample, resulting in the chromophoric moiety changing its radiation absorption properties in the ultraviolet and visible regions of the spectrum. For example, a change in an intensity of an absorption maximum is measured and the ion concentration is determined accordingly.
摘要翻译：本发明涉及测定样品中钾离子的方法，其中离子与具有发色部分和离子部分的化合物接触，其中离子部分与样品中存在的钾离子相互作用，导致发色部分改变其紫外线和可见光谱区的辐射吸收特性。例如，测量吸收最大强度的变化，并且相应地确定离子浓度。

2. 发明申请

WO2007131054A3 CHROMOIONOPHORE AND METHOD OF DETERMINING SODIUM IONS 审中-公开
公开(公告)号：WO2007131054A3
公开(公告)日：2007-11-15
申请号：PCT/US2007/068060
申请日：2007-05-02
申请人： OPTI MEDICAL SYSTEMS , HE, Huarui , LIN, Chao , RAJE, Neeta , LIU, Chuseng
发明人： HE, Huarui , LIN, Chao , RAJE, Neeta , LIU, Chuseng
IPC分类号： G01N21/75 , G01N23/00 , G01N21/00 , G01N21/62 , G01N21/76 , C09K3/00
摘要： The invention relates to methods of determining sodium ions in a sample, wherein the ions are contacted with a compound having chromophoric moiety and an ionophoric moiety, where the ionophoric moiety interacts with the sodium ions present in the sample, resulting in the chromophoric moiety changing its radiation absorption properties in the ultraviolet and visible regions of the spectrum. For example, a change in an intensity of an absorption maximum is measured and the ion concentration is determined accordingly.

3. 发明申请

WO2007131048A3 CHROMOIONPHORE AND METHOD OF DETERMINING CALCIUM IONS 审中-公开
公开(公告)号：WO2007131048A3
公开(公告)日：2007-11-15
申请号：PCT/US2007/068053
申请日：2007-05-02
申请人： OPTI MEDICAL SYSTEMS, INC. , HE, Huarui , LIN, Chao
发明人： HE, Huarui , LIN, Chao
IPC分类号： G01N33/20
摘要： The invention relates to methods of determining calcium ions in a sample, wherein the ions are contacted with a compound having chromophoric moiety and an ionophoric moiety, where the ionophoric moiety interacts with the calcium ions present in the sample, resulting in the chromophoric moiety changing its radiation absorption properties in the ultraviolet and visible regions of the spectrum. For example, a change in an intensity of an absorption maximum is measured and the ion concentration is determined accordingly.

4. 发明申请

WO2011011605A1 HYDROGEN PEROXIDE SENSORS BASED UPON PHOTO-INDUCED ELECTRON TRANSFER 审中-公开
标题翻译：过氧化氢传感器基于光电导电传输
公开(公告)号：WO2011011605A1
公开(公告)日：2011-01-27
申请号：PCT/US2010/042910
申请日：2010-07-22
申请人： OPTI MEDICAL SYSTEMS , HE, Huarui , LIN, Chao
发明人： HE, Huarui , LIN, Chao
IPC分类号： C07F15/00 , A61B5/00
CPC分类号： C07D221/14 , C07D401/12 , Y10T436/206664
摘要： The invention provides compounds of formula I F-L-Q (I) where F comprises a fluorophore capable of absorbing energy at an excitation wavelength and, in the absence of a quencher, emitting energy at an emission wavelength, which is different than the excitation wavelength; Q comprises a quencher; L comprises a linker moiety having two ends, one end being covalently bound to F and the other end being covalently bound to Q. The compounds are capable of undergoing a reversible reaction (1), provided below: (1) where Q + is an oxidized form of Q representing the absence of a quencher, Ox comprises an oxidizing agent, which is capable of oxidizing Q to its oxidized form Q, and Red comprises a reducing agent, which is capable of converting Q back to its reduced form Q. The compounds can undergo photo-induced electron transfer when irradiated with energy and when Q exists in its oxidized form, Q + . The invention also provides methods of detecting and determining the presence of analytes and/or hydrogen peroxide in a sample, as well as a substrate that comprises the compound of formula I.
摘要翻译：本发明提供式I F-L-Q（I）的化合物，其中F包括能够在激发波长处吸收能量的荧光团，并且在不存在猝灭剂的情况下发射不同于激发波长的发射波长的能量; Q包括猝灭剂; L包含具有两个末端的连接部分，一端与F共价结合，另一端与Q共价结合。化合物能够经历可逆反应（1），其如下：（1）其中Q +是氧化的形式Q表示不存在猝灭剂，Ox包含氧化剂，其能够将Q氧化成其氧化形式Q，并且Red包含还原剂，其能够将Q转化为其还原形式Q.化合物当能量照射时，当Q以其氧化态存在时，可以进行光诱导电子转移。本发明还提供了检测和确定样品中分析物和/或过氧化氢的存在以及包含式I化合物的底物的方法。

5. 发明申请

WO2008073255A2 SPREADING LAYER AND HUMIDITY CONTROL LAYER FOR ENHANCING SENSOR PERFORMANCE 审中-公开
标题翻译：扩展层和湿度控制层，以提高传感器性能
公开(公告)号：WO2008073255A2
公开(公告)日：2008-06-19
申请号：PCT/US2007/024942
申请日：2007-12-06
申请人： OPTI MEDICAL SYSTEMS , RAMAMURTHY, Narayanan , HE, Huarui , LIN, Chao
发明人： RAMAMURTHY, Narayanan , HE, Huarui , LIN, Chao
IPC分类号： B01D69/14 , B01J20/28 , G01N33/18 , B01D69/10 , G01N33/52
CPC分类号： G01N33/525 , B01D2253/202 , B01D2257/80 , B01J20/28033 , B01J20/28097 , G01N21/274 , G01N21/6428 , G01N21/8483 , G01N2021/7786 , Y10T428/24273 , Y10T428/265 , Y10T428/31504
摘要： The invention is directed to optical sensors for measuring clinically relevant analytes, their methods of manufacture, and their various uses. In an effort to develop a dry calibration method for the optical sensors of the invention it is discovered that water content inside or in the immediate vicinity of a such a sensor can have a major impact on fluorescence intensity (i.e., a sensor's response in the dry state). Thus, one of the objectives of the invention is the elimination of the bias of sensor responses measured at different humidity environments.
摘要翻译：本发明涉及用于测量临床相关分析物，其制造方法及其各种用途的光学传感器。为了开发用于本发明的光学传感器的干式校准方法，发现这种传感器内部或附近的含水量可能对荧光强度具有主要影响（即传感器在干燥时的响应）州）。因此，本发明的目标之一是消除在不同湿度环境下测量的传感器响应的偏差。

6. 发明申请

WO2003076937A3 APPARATUS AND METHODS FOR ANALYTE MEASUREMENT AND IMMUNOASSAY 审中-公开
公开(公告)号：WO2003076937A3
公开(公告)日：2003-09-18
申请号：PCT/US2003/006820
申请日：2003-03-05
申请人： I-STAT CORPORATION , DAVIS, Graham , LAUKS, Imants, R. , LIN, Chao , MILLER, Cary, James
发明人： DAVIS, Graham , LAUKS, Imants, R. , LIN, Chao , MILLER, Cary, James
IPC分类号： G01N33/483
摘要： The present invention relates to an apparatus for conducting a variety of assays for the determination of analytes in liquid samples, and relates to the methods for such assays. In particular, the invention relates to a single-use cartridge designed to be adaptable to a variety of real-time assay protocols, preferably assays for the determination of analytes in biological samples using immunosensors or other ligand/ligand receptor-based biosensor embodiments. The cartridge provides novel features for processing a metered portion of a sample, for precise and flexible control of the movement of a sample or second fluid within the cartridge, for the amending of solutions with additional compounds during an assay, and for the construction of immunosensors capable of adaptation to diverse analyte measurements. The disclosed device and methods of use enjoy substantial benefits over the prior art, including simplicity of use by an operator, rapid in situ determinations of one or more analytes, and single-use methodology that minimizes the risk of contamination of both operator and patient. The disclosed invention is adaptable to the point-of-care clinical diagnostic field, including use in accident sites, emergency rooms, surgery, nursing homes, intensive care units, and non-medical environments.

7. 发明申请

WO2006039488A2 HCV NS3-NS4A PROTEASE INHIBITION 审中-公开
公开(公告)号：WO2006039488A2
公开(公告)日：2006-04-13
申请号：PCT/US2005/035191
申请日：2005-09-30
申请人： VERTEX PHARMACEUTICALS INCORPORATED , LIN, Chao , TAYLOR, William, P.
发明人： LIN, Chao , TAYLOR, William, P.
IPC分类号： A61K38/05
CPC分类号： A61K45/06 , A61K31/42 , A61K31/425 , A61K31/497 , A61K31/7056 , A61K38/07 , A61K38/21 , A61K2300/00
摘要： The present invention relates to inhibiting the activity of non-genotype 1 hepatitis C virus (HCV) NS3-NS4A protease activity. More particularly, the invention relates to inhibiting the activity of the protease from HCV genotype-2 or HCV genotype-3. The methods of the invention emply inhibitors that act by interfering with the life cycle of the HCV and are also useful as antiviral agents. The invention further relates to compositions comprising such compounds either for ex vivo use or for administration to a patient suffering from genotype-2 or genotype-3 HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
摘要翻译：本发明涉及抑制非基因型1丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的活性。更具体地，本发明涉及抑制来自HCV基因型-2或HCV基因型-3的蛋白酶的活性。本发明的方法通过干扰HCV的生命周期而起作用的抑制剂，并且还可用作抗病毒剂。本发明还涉及包含用于离体使用或用于给予基因型-2或基因型-3 HCV感染的患者的这些化合物的组合物。本发明还涉及通过施用包含本发明化合物的组合物来治疗患者HCV感染的方法。

8. 发明申请

WO2005042570A1 HCV NS3-NS4A PROTEASE RESISTANCE MUTANTS 审中-公开
标题翻译： HCV NS3-NS4A抗性突变体
公开(公告)号：WO2005042570A1
公开(公告)日：2005-05-12
申请号：PCT/US2004/035839
申请日：2004-10-27
申请人： VERTEX PHARMACEUTICALS INCORPORATED , LIN, Chao , LIN, Kai
发明人： LIN, Chao , LIN, Kai
IPC分类号： C07K14/18
CPC分类号： G01N33/6818 , A61K38/162 , C12N9/506 , C12Q1/37 , C12Q1/707 , C12Q2600/156 , G01N2333/18
摘要： The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.
摘要翻译：本发明涉及HCV NS3 / 4A蛋白酶的突变体。更具体地，本发明鉴定对药物治疗有抗性的HCV NS3 / 4A蛋白酶的突变体。

9. 发明申请

WO2003035260A1 METHOD AND APPARATUS FOR HIGH-THROUGHPUT SAMPLE HANDLING PROCESS LINE 审中-公开
标题翻译：用于高通量样品处理工艺线的方法和装置
公开(公告)号：WO2003035260A1
公开(公告)日：2003-05-01
申请号：PCT/US2002/034640
申请日：2002-10-25
申请人： SEQUENOM, INC. , GROHMANN ENGENEERING GMBH , LIN, Chao , YAO, Xian-Wei , JANSEN, Johannes , HEANEY, Paul , NANTHAKUMAR, Elizabeth , BRAULIO, Wilbur , LIANG, Ben , GROHMANN, Klaus , UNGER, Sigfried
发明人： LIN, Chao , YAO, Xian-Wei , JANSEN, Johannes , HEANEY, Paul , NANTHAKUMAR, Elizabeth , BRAULIO, Wilbur , LIANG, Ben , GROHMANN, Klaus , UNGER, Sigfried
IPC分类号： B01L3/02
CPC分类号： G01N35/1065 , B01J2219/00274 , B01J2219/00315 , B01J2219/00364 , B01J2219/00369 , B01J2219/00466 , B01J2219/005 , B01L3/0217 , B01L3/0241 , B01L3/0244 , B01L7/02 , B01L7/52 , B01L9/52 , B01L2200/022 , B01L2200/0657 , B01L2200/143 , B01L2300/0829 , B01L2300/185 , C40B60/14 , G01N35/028 , G01N35/1011 , G01N35/1074 , G01N2035/00168 , G01N2035/00207 , G01N2035/00326 , G01N2035/00346 , G01N2035/00574
摘要： Disclosed is a process line system (100) for handling biological samples. The system includes a control computer (101) that controls the movement of a sample material plate along the process line. The control computer accepts user inputs that define handling of the biological samples. The system further includes a plurality of modules (112, 114, 116, 118, 120, 122) arranged along the process line. Each module includes at least one work station that performs at least one task associated with the handling of the biological samples. The control computer adjusts the movement of the sample material plate along the process line so that the sample material plate is transported to only those modules that are to handle the biological sample, and so that the sample material plate bypasses any module that should not handle the biological sample, as defined by the user inputs.
摘要翻译：公开了一种用于处理生物样品的生产线系统（100）。该系统包括控制计算机（101），其控制样品材料板沿着生产线的移动。控制计算机接受定义生物样品处理的用户输入。该系统还包括沿着生产线布置的多个模块（112,114,116,118,120,122）。每个模块包括执行与生物样品的处理相关联的至少一个任务的至少一个工作站。控制计算机调节样品材料板沿着生产线的移动，使样品材料板仅被传送到那些要处理生物样品的模块，并且使得样品材料板绕过任何不应该处理生物样品的模块生物样品，由用户输入定义。

10. 发明申请

WO2010090857A2 METHODS FOR AMPLIFYING HEPATITIS C VIRUS NUCLEIC ACIDS 审中-公开
标题翻译：扩增丙型肝炎病毒核酸的方法
公开(公告)号：WO2010090857A2
公开(公告)日：2010-08-12
申请号：PCT/US2010/021589
申请日：2010-01-21
申请人： VERTEX PHARMACEUTICALS INCORPORATED , KWONG, Ann, D. , FRANTZ, James, Daniel , BARTELS, Douglas, J. , LIN, Chao , SHAMES, Benjamin , SEEPERSAUD, Sheila , LIPPKE, Judith, A. , KIEFFER, Tara, L. , ZHOU, Yi , ZHANG, Eileen, Z. , SULLIVAN, James, C.
发明人： KWONG, Ann, D. , FRANTZ, James, Daniel , BARTELS, Douglas, J. , LIN, Chao , SHAMES, Benjamin , SEEPERSAUD, Sheila , LIPPKE, Judith, A. , KIEFFER, Tara, L. , ZHOU, Yi , ZHANG, Eileen, Z. , SULLIVAN, James, C.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/707 , C12Q1/6883
摘要： A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11. The nucleotide sequence of the first inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 5; or SEQ ID NO: 12, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 12. The nucleotide sequence of the second inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 6 or 7; or a nucleotide sequence as set forth in SEQ ID NO: 13 or 14, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 13 and 14.
摘要翻译：扩增HCV感染样品中的HCV核酸的方法包括通过两阶段PCR扩增与来自样品的HCV RNA基因组互补的DNA模板片段，其中a 第一阶段PCR使用第一外部引物和第二外部引物，并且第二阶段PCR使用第一内部引物和第二内部引物。第一外部引物的核苷酸序列包含如SEQ ID NO：2所示的核苷酸序列; 或SEQ ID NO：9的核苷酸序列，其中任选地1,2或3个核苷酸是除SEQ ID NO：9的核苷酸以外的核苷酸。第二外部引物的核苷酸序列包含SEQ ID NO：3或4所示的核苷酸序列; 或如SEQ ID NO：10或11所示的核苷酸序列，其中任选地1,2或3个核苷酸是与SEQ ID NO：10和11的那些核苷酸不同的核苷酸。第一内部引物的核苷酸序列包含核苷酸序列如SEQ ID NO：5所示; 或SEQ ID NO：12，其中任选地1,2或3个核苷酸是不同于SEQ ID NO：12的核苷酸。第二内部引物的核苷酸序列包含如SEQ ID NO：6或7所示的核苷酸序列 ; 或如SEQ ID NO：13或14所示的核苷酸序列，其中任选地1,2或3个核苷酸是不同于SEQ ID NO：13和14的那些核苷酸。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式